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Background. Mesenchymal stem cells (MSCs) emerged as a promising therapy for tendon pathologies. Microfragmented adipose
tissue (μFAT) represents a convenient autologous product for the application of MSC-based therapies in the clinical setting. In
the present study, the ability of μFAT to counteract inflammatory processes induced by IL-1β on human tendon cells (TCs) was
evaluated. Methods. Cell viability and proliferation were evaluated after 48 hours of transwell coculture of TCs and autologous
μFAT in the presence or absence of IL-1β. Gene expression of scleraxis, collagen type I and type III, metalloproteinases-1 and -3,
and cyclooxygenase-2 was evaluated by real-time RT-PCR. The content of VEGF, IL-1Ra, TNFα, and IL-6 was evaluated by
ELISA. Results. IL-1β-treated TCs showed augmented collagen type III, metalloproteases, and cyclooxygenase-2 expression. μFAT
was able to reduce the expression of collagen type III and metalloproteases-1 in a significant manner, and at the same time, it
enhanced the production of VEGF, IL-1Ra, and IL-6. Conclusions. In this in vitro model of tendon cell inflammation, the
paracrine action of μFAT, exerted by anti-inflammatory molecules and growth factors, was able to inhibit the expression of
fibrosis and catabolic markers. Then, these results suggest that the application of μFAT may represent an effective conservative or
adjuvant therapy for the treatment of tendon disorders.
1. Introduction
Tendon disorders represent a common condition in the field
of musculoskeletal injuries. Current treatment options often
lead to unsatisfactory results, with persistence of pain and
reduced physical activity level [1, 2]. Among the conservative
approaches, the use of mesenchymal stem cells (MSCs) from
the bone marrow and adipose tissue emerged as a promising
treatment, capable to counteract the pathological processes
characterizing degenerative disease in the orthopedic field
[3], gathering interest also in the treatment of tendon disor-
ders. Indeed, successful applications of cultured MSCs were
described for the treatment of tendon injuries in preclinical
models [4]. The use of adipose-derived stem cells (ASCs),
or autologous adipose-derived products, already showed effi-
cacy in the context of tendon disorders in clinical and pre-
clinical trials [5–8]. In vitro investigations demonstrated
that the coculture of ASCs or μFAT improved proliferation,
viability, and collagen and VEGF production in tendon cells
(TCs) [9, 10]. In addition, in an in vitro model of TC inflam-
mation, cultured adipose-derived MSCs were able to reduce
the production of proinflammatory mediators [11]. Never-
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theless, translation of MSC-based therapies implies extensive
manipulation for the production of cells in good manufactur-
ing practice (GMP) conditions and it is limited by the high
costs of production and the regulatory issues related to the
advanced therapy medicinal products [12, 13]. As a conse-
quence, different solutions for adipose- and bone marrow-
derived MSC isolation at the point of care have been
proposed in recent years, with encouraging results [5, 14].
In particular, microfragmented adipose tissue (μFAT) repre-
sents a convenient compromise for the exploitation of MSCs
in the clinical practice, avoiding extensive cell manipulation,
and culture expansion [15]. μFAT is easily obtained by com-
mercially available devices from autologous lipoaspirate, and
it has been demonstrated to exert a therapeutic activity in
clinical and preclinical settings, providing positive functional
outcomes in particular for the treatment of knee osteoarthri-
tis [16–20]. The procedure of μFAT production and injection
is compatible with a single-stage surgery and may be com-
bined with different surgical procedures. The aim of the pres-
ent study was to investigate the paracrine effect of μFAT on
the proinflammatory and catabolic response of TCs to tnter-
leukin-1β- (IL-1β-) mediated inflammation. This molecule
has been described as the primary mediator of the inflamma-
tory status preventing tissue healing in rotator cuff injury
[21], and previous reports showed that IL-1β-treated TCs
upregulated the expression of catabolic enzymes and the
production of inflammatory cytokines [22–24]. Thus, the
working hypothesis of the present study is that autologous
μFAT would counteract the catabolic and proinflammatory
response elicited by IL-1β on TCs, providing insights on
the mechanism of action of this therapeutic approach and
strengthening the rationale of its use in tendon disorders.
2. Materials and Methods
2.1. TCs and μFAT Isolation and Harvesting. Long head of
biceps tendon biopsies and μFAT were collected from 8
patients (5 females and 3 males, mean age: 60 ± 10 y/o)
undergoing arthroscopic rotator cuff repair augmented with
μFAT. An informed consent was obtained from all patients
as per the protocol approved by the Institutional Review
Board (no. 148/INT/2015, January 13, 2016). Lipoaspirate
adipose tissue was collected before surgery and processed
by Lipogems® device, following the manufacturer’s instruc-
tion [25]. An aliquot of μFAT was harvested for in vitro
experiments. Briefly, each μFAT sample was centrifuged at
376 × g for 5 minutes at room temperature to separate the
aqueous phase and the fragmented tissue. The former was
stored at -20°C, while the latter was frozen at -80°C after
the addition of 1 volume of freezing solution (90% FBS,
10% dimethyl sulfoxide; Sigma-Aldrich, St. Louis, MO,
USA). Separation of the two phases was adopted to maintain
the composition of injected μFAT even after thawing and
removal of the aqueous freezing solution. This allowed for
the use in the experiment of an identical product as injected
during the surgical procedure.
Human tendon cells (TCs) were isolated from long head
of the biceps tendon biopsies obtained during arthroscopic
rotator cuff repair. Tendon tissue was digested with a 0.3%
w/v collagenase type I solution (Worthington, Lakewood,
NJ, USA) for 16 hours at 37°C, as previously reported [26].
TCs were cultured in a complete medium composed by
high-glucose Dulbecco’s modified Eagle’s medium (DMEM;
Sigma-Aldrich) with 10% v/v fetal bovine serum (FBS;
Euroclone, Pero, Italy), 100U/ml penicillin, 100μg/ml
streptomycin, 0.29mg/ml L-glutamine (Gibco, Waltham,
MA, USA), and 5ng/ml bFGF (Peprotech, London, UK).
The medium was replaced every 3 days, and all the experi-
ments have been performed at passage 3. After culture, TCs
represent a mixed population of terminally differentiated
and tendon progenitor cells at different stages of differentia-
tion, as previously reported [26, 27].
2.2. Treatment of TCs with IL-1β and Coculture with μFAT.
TCs were seeded in 12-well plates at the density of 50000
cells/well. TCs were either maintained in normal culture
medium or a medium added of 1 ng/ml IL-1β. In addition,
cells treated with IL-1β and untreated cells were cocultured
with 250μl of μFAT, made of125μl of microfragmented tis-
sue and 125μl of the corresponding aqueous phase. The
two phases were separated in order to maintain the aqueous
part of μFAT, even after thawing and removal of the freezing
solution. μFAT was added to the top portion of a transwell
insert (pore size: 0.4μm), while TCs were seeded on the bot-
tom. Equal volume of phosphate-buffered saline (PBS) was
added in the transwell top portion of the samples without
μFAT. After 48 hours of treatment, the culture media were
collected and stored at -20°C, while cells were trypsinized
and the pellets stored at -80°C.
2.3. RNA Isolation and Gene Expression. RNA was obtained
from cell pellets using TRI reagent (Sigma-Aldrich). Briefly,
cells were lysed by the addition of 300μl TRI reagent, and
then 100μl of 1-bromo-3-chloropropane (Sigma-Aldrich)
were added to the samples. After centrifugation at 12000 × g
for 10 minutes, the interphase was collected for DNA extrac-
tionwhile theRNA in the aqueous phasewas precipitatedwith
isopropanol, washed in 75% ethanol and then resuspended in
20μl RNAse-free water for storage at -80°C.
Total RNA from each sample was transcribed to cDNA
using iScript™ cDNA Synthesis Kit (Bio-Rad Laboratories,
Hercules, CA, USA) as per manufacturer’s instructions.
Real-time PCR was performed starting from 10ng of
cDNA, using a PCR mix containing TaqMan® Universal
PCR Master Mix and Assays-on-Demand Gene expression
probes (Life Technologies, Waltham, MA, USA) for SCX
(scleraxis; Hs03054634_g1), COL1A1 (collagen type I alpha 1
chain; Hs01076777_m1), COL3A1 (collagen type III alpha 1
chain; Hs00943809_m1), MMP1 (metalloproteinase-1;
Hs00899658_m1), MMP3 (metalloproteinase-3;
Hs00968305_m1), and PTGS2 (cyclooxygenase-2;
Hs00153133_m1). Applied Biosystems StepOnePlus® (Life
Technologies) was used to perform all experiments
(program: 1 cycle of 2 minutes at 50°C, 1 cycle of 10 minutes
at 95°C, 40 cycles of 15 seconds at 95°C, and 1 minute at
60°C). The results were normalized against the mean
expression of two housekeeping genes: YWHAZ (tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation
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protein zeta, Hs03044281_g1) and ACTB (β-actin,
Hs99999903_m1) identified in a previous study [28]. Two
replicates were analyzed for each sample, and data were
presented according to the ΔΔCtmethod [29].
2.4. DNA Isolation and Quantification. DNA was separated
from the interphase (obtained as described above) by the
addition of 100% ethanol and centrifugation at 2000 × g for
5 minutes. The DNA pellet was washed in 0.1M trisodium
citrate, 10% ethanol solution for 30 minutes, and then centri-
fuged at 2000 × g for 5 minutes. DNA was then washed in
75% ethanol, and solubilized in 50μl 8mM NaOH for stor-
age at -20°C. DNA content in each sample was measured
by NanoDrop spectrophotometer at 260nm absorbance
using software version 3.7.1 (NanoDrop ND-1000, Thermo-
Fisher Scientific) [30].
2.5. TC Metabolic Activity. Viability was assessed by
alamarBlue assay after 48 hours of treatment (ThermoFisher
Scientific, Waltham, MA, USA). Briefly, culture medium was
removed and cells were incubated with a 10% v/v solution of
alamarBlue in DMEM at 37°C. After 2 hours of incubation,
fluorescence was measured by a spectrophotometer (Victor
X3, Perkin Elmer, Waltham, MA, USA) with excitation of
540nm and emission of 590nm.
2.6. ELISA.The release of interleukine-6 (IL-6), interleukine-1
receptor antigen (IL-1Ra), tumor necrosis factor α (TNFα)
(Peprotech), and vascular endothelial growth factor (VEGF)
(R&D Systems, Minneapolis, MN, USA) in the culture media
of TCs treated for 48 hours was analyzed by ELISA assays, fol-
lowing the manufacturer’s instruction. The detection ranges
were as follows: 24–1500 pg/mL for IL-6, 23–1500 pg/mL
for IL-1Ra, 31-2000 pg/ml for TNFα, and 31.3-2000pg/ml
for VEGF.
2.7. μFAT Cell Count and Viability Assays. After thawing, an
aliquot of μFAT was digested by 0.075%w/v collagenase type
I (Worthington) for 45 minutes at 37°C. The number of cells
and viability was assessed by NucleoCounter NC-3000 using
cell viability staining (Chemometech, Allerod, Denmark)
[31]. The μFAT samples used in the study had a mean cell
count of 2:3 ± 1:3 × 106 cells/ml, while cell viability was
53:2 ± 13:1%.
2.8. Statistical Analysis. All the analyses were performed
using Prism 5.0 (Graphpad Software, La Jolla, CA, USA).
Gaussian distribution of data was assessed by Shapiro-Wilk
test. One-way repeated measures ANOVA test with Bonfer-
roni’s post test was applied to measure the differences among
treatments when data presented a Gaussian distribution
(Figures 1(a), 2(b), and 2(c)); otherwise, the Friedman’s test
with Dunn’s post-test was used (Figures 1(b), 2(a), and 3).
A level of p < 0:05 was considered statistically significant.
3. Results
3.1. IL-1β and μFAT Enhance TC Metabolic Activity. The
metabolic activity of IL-1β-treated TCs was significantly
increasedwith respect to untreatedTCs (p < 0:01), and no fur-
ther improvement was induced by the coculture with μFAT.
In noninflammatory conditions, samples cocultured in
transwell with μFAT demonstrated a higher metabolic activ-
ity with respect to untreated TCs (p < 0:05) (Figure 1(a)).
DNA content resulted in increased in all conditions, even if
in a nonsignificant manner (Figure 1(b)).
3.2. μFAT Reduces the Gene Expression of Catabolic and
Fibrosis Markers. The presence of IL-1β significantly
enhanced the TC expression of SCX (p < 0:05), MMP1
(p < 0:01), MMP3 (p < 0:01), COL3A1 (p < 0:001), and
PTGS2 (p < 0:01) with respect to untreated TCs, while it
did not exert any effect on COL1A1 expression (Figure 3).
In this inflammatory condition, the coculture with μFAT
decreased the expression of COL3A1 (-57%, p < 0:001) and
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Figure 1: Metabolic activity (a) and DNA content (b) of untreated and differently treated TC samples (n = 8). ∗p < 0:05, ∗∗∗p < 0:001 vs. TCs.
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MMP1 (-41%, p = 0:08) (Figures 3(c) and 3(d)), with little
effect on the other parameters. No effect of μFAT on
MMP3 expression was observed, while it was strongly
induced by IL-1β treatment (Figure 3(e)). Moreover, TCs
cocultured with μFAT, with or without IL-1β, showed a
reduced expression of COL1A1 with respect to untreated
TCs (p = 0:06 and p < 0:001 in the presence or absence of
IL-1β, respectively) (Figure 3(b)). A slight increase in SCX
expression was observed in TCs cocultured with μFAT and
treated with IL-1β, with respect to IL-1β only treated cells
(+12%, n.s.) (Figure 3(a)).
A fivefold increase in overall COL3A1/COL1A1 expres-
sion ratio was observed in IL-1β-treated TCs with respect
to untreated TCs (p < 0:05, data not shown). In inflammatory
conditions (+IL-1β), the coculture with μFAT was able to
reduce the ratio, even if in a nonstatistically significant
manner (-27%, n.s.), while in TCs+μFAT, the ratio was
increased in a nonsignificant manner in comparison to
untreated TCs samples, in both inflammatory and nonin-
flammatory conditions.
3.3. Il-1β and μFAT Enhance the Production of Cytokines and
VEGF. In the presence of IL-1β, an enhanced production of
IL-6 (p < 0:001) was observed with respect to untreated
TCs, and it was further increased by the coculture with μFAT
(+45%, p < 0:05with respect to TCs+IL-1β) (Figure 2(a)). On
the contrary, IL-1Ra production was not induced by IL-1β or
μFAT alone, while the contemporary presence of these fac-
tors significantly increased the production of this molecule
(+217% and +290%, with respect to both untreated TCs
and IL-1β-treated TCs; p < 0:05) (Figure 2(b)). The produc-
tion of VEGF was induced by IL-1β (+109% with respect to
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Figure 2: IL-1Ra, IL-6, and VEGF quantification in culture media of TCs treated with IL-1β and/or μFAT and untreated TCs (n = 8).
∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001 vs. TCs; ##p < 0:01, ###p < 0:001 vs. +μFAT; §p < 0:05 vs. +IL-1β.
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Figure 3: Gene expression of SCX, COL1A1, COL3A1, MMP1, MMP3, and PTGS2 in TCs cultured in the presence of IL-1β and/or μFAT
(n = 8). Data are expressed as mean ΔΔCt with respect to untreated controls (TCs = 1). ∗p < 0:05, ∗∗p < 0:01, ∗∗∗p < 0:001 vs. TCs;
#p < 0:05, ###p < 0:001 vs. +μFAT; §§§p < 0:001 vs. +IL-1β; $p < 0:1 vs. +IL-1β (tendency).
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untreated cells, p < 0:05) or μFAT coculture (+116% with
respect to untreated cells, p < 0:05); the combination of
both factors further increased VEGF production (+29%
in comparison with TCs treated with IL-1β, p < 0:05)
(Figure 2(c)). The content of TNFα was undetectable in
all samples (data not shown).
4. Discussion
The present study aimed to test the ability of autologous
μFAT in favouring tissue healing in the context of tendon cell
inflammation. Our results demonstrated that the paracrine
action of μFAT effectively reduces the expression of catabolic
and fibrosis markers in pair-matched TCs cultured in inflam-
matory conditions. The strength of this work is the use of
patient-matched TCs and μFAT, allowing for taking into
account the inter-donor variability in both elements.
More in details, in cells exposed to IL-1β, the paracrine
action of μFAT was able to significantly reduce the COL3A1/-
COL1A1 ratio which positively correlates with the deposition
of rupture-prone fibrotic tendon matrix [32, 33], confirming
previous findings obtained in cocultures of TCs and
adipose-derived MSCs [34, 35]. IL-1β has been described
as the key effector of tendon inflammation leading to the
inhibition of the proper healing process [21, 23, 24], also
enhancing the production of catabolic enzymes such as
MMP1 and MMP3 involved in tendon matrix degradation
[36, 37], and increasing collagen type III expression over
collagen type I. Moreover, IL-1β directly induces the pro-
duction of the enzyme cyclooxygenase-2 (COX-2), typical
marker of inflammation [38]. Interestingly, cells cultured in
inflammatory condition in presence of μFAT showed an
overall reduction of the absolute expression of both collagen
type I and III. The increase in collagen type III after injury is
associated with the formation of scar tissue, which allows for
prompt healing at the expense of tissue quality and function-
ality [39, 40]. In this view, a slower matrix deposition, where
the proportion between the different types of collagen is sim-
ilar to the physiological level, represents a therapeutic goal
aimed to improve the quality of regenerated tissue.
In addition, μFAT was able to inhibit MMP1 expression,
suggesting a protective role towards tendon ECM integrity.
Metalloproteases are crucial for the physiological mainte-
nance of tendon extracellular matrix (ECM) homeostasis
[41], to the extent that the inhibition of MMPs results in
pathological changes and pain [42]. On the other hand, an
excess of MMP expression is associated with aberrant matrix
degradation, typical of degenerative tendon disorders [43]. In
particular, MMP1 is clearly involved in tendon pathology in
association with the action of IL-1β [44, 45]. The effect of
μFAT on MMP expression is consistent with previous obser-
vations reported in a model of inflamed synoviocytes, sup-
porting the inhibition of MMP-related matrix degradation
as a mechanism of action of this product [46]. Moreover,
when inflammatory processes are not involved, μFAT has lit-
tle effect on the expression of MMPs, indicating that it would
not inhibit the physiological remodeling of tendon ECM.
In this study, the influence of IL-1β on the expression of
the tendon-specific transcription factor SCX was also
assessed. While previous reports showed an inhibition of
its transcription in inflammatory conditions [23, 47, 48], in
our model, the presence of IL-1β significantly increased SCX
expression. The discrepancy between the results described in
literature and those reported in the present study is probably
due to the different sources of TCs and to the inflammatory
protocol. Since adipose-derived MSCs are known to produce
trophic mediator-specific for TCs [49], a slight reduction of
SCX expression was observed when TCs were cocultured with
μFAT in basal conditions, and a downregulation of this
marker have been already reported by other authors after
TCs-MSCs coculture [34]. These observations suggest that
μFAT (or MSCs) trophic action on TCs may be independent
of SCX upregulation.
Our findings showed no effect of μFAT on PTGS2
expression, neither in inflammatory nor in noninflamma-
tory conditions. As expected, PTGS2 transcription was
enhanced by IL-1β treatment with respect to basal condi-
tions, being IL-1β the main inducer of this gene encoding
for COX2 [38]. Despite its role in inflammation, COX2 has
been reported exerting an important role in the maintenance
of tendon homeostasis and ECMmaturation [50, 51]. There-
fore, the expression of this enzyme may represent not only as
a symptom of inflammation but also as a response of TCs
towards tissue healing.
IL-1β and μFAT both demonstrated an enhancing effect
on TC metabolic activity and DNA content, even if no statis-
tical significance was found for the latter. Interestingly, this
effect was not further enhanced by the use of IL-1β on TCs
cocultured with μFAT, showing a lack of additive/synergistic
action of the two elements on these parameters.
In our model, due to the use of a transwell system, the
modifications induced by μFAT on TC gene expression and
metabolic activity are ascribed to its paracrine activity. In
particular, μFAT increased the content of soluble IL-1Ra,
IL-6, and VEGF in the culture medium. IL-1Ra is a direct
inhibitor of IL-1β, and it acts by competing with the cyto-
kines for the binding to IL-1 receptor 1 [52], to the extent that
IL-1Ra-based treatments have been developed for rheu-
matoid arthritis and other autoinflammatory diseases [53].
IL-1Ra production was elicited in μFAT samples only in
the presence of inflammatory conditions, suggesting it is a
reaction of the μFAT-embedded adipose-derived MSCs to
this condition. Indeed, these cells are known to respond to
IL-1β stimulation by releasing IL-1Ra [54], as well as MSCs
from other sources [55].
As expected, in our model, the content of IL-6 was
enhanced in the presence of IL-1β [56] and μFAT further
increased its production. This effect is possibly related to
the IL-1β-mediated induction of IL-6 in the cells contained
in μFAT [54], and even if there are little evidences of direct
pathological changes mediated by IL-6 on TCs and tendon
matrix production [57], this aspect should be taken into
account as a possible side effect when applying cell-based
regenerative medicine products. The role of IL-6 in tendon
pathologies has been confirmed by several studies, and it is
considered one of the evidences of inflammation involve-
ment in tendinopathy [58]. Indeed, IL-6 increased after tears
and ruptures, as well as after intense exercise and injuries, in
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both humans and animals [59]. Nevertheless, despite its role
in inflammation, IL-6 exhibits an immunoregulatory activity
and it demonstrated to support tenocyte proliferation and
survival, thus resulting among the effectors of the early
phases of tendon healing [60–62]. In addition, IL-6 induces
the production of VEGF [63], a growth factor mainly known
for its role in angiogenesis, that is also involved in tissue
regeneration, exerting a homeostatic function [64]. Different
to what is observed in IL-6, VEGF is induced by both IL-1β
and μFAT treatments at similar intensities, and it was further
enhanced by the combination of these factors. Then, since
IL-6 was just slightly enhanced by μFAT treatment in com-
parison to untreated TCs, the μFAT-induced VEGF produc-
tion appears to be at least partially independent from the IL-6
pathway. Despite the promotion of angiogenesis which may
result detrimental for tendon ECM integrity [65], VEGF
was able to improve tendon healing strength in several
studies [66–68].
The ability of MSCs and μFAT paracrine mediators to
counteract inflammation is well described, and it has been
reported in several models involving different cells and tis-
sues, comprising chondrocytes, synoviocytes, and the central
nervous system [46, 69, 70]. Indeed, the increased production
of VEGF and the augmented expression of SCX and, to
some extent, COL3A1, demonstrate that IL-1β also elicits
an initial reparative response in TCs [71]. This observation
is consistent with the presence of a subpopulation of pro-
genitor cells, demonstrating features of mesenchymal
stem/stromal cells, within TCs [26, 72]. In pathological
conditions and aging, the presence of progenitor cells may
be reduced, leading to a loss of homeostatic function and thus
tissue degeneration [73]. Then, the idea to supply the injured
tissue with a convenient source of autologous MSCs with
homeostatic and immunomodulatory activity perfectly rep-
resents the rationale of the application of cell concentrates
in degenerative disorders.
Limitations of the present study are represented by the
use of a nonphysiological inflammatory stimulus that may
result in considerably stronger than the one occurring
in vivo, and thus partially masking the ability of μFAT to
counteract the catabolic response. In addition, the quantity
of μFAT was chosen based on previous reports [9], but the
proportion between cells and tissue hardly corresponds to
the physiological ratio. Another limitation is given by the
possible influence of patients’ characteristics on the activity
of μFAT, which was not taken into account in the present
work while it may indeed identify a fraction of individuals
who are nonresponders to the μFAT treatment due to pathol-
ogy or adipose tissue-specific features [74] and thus repre-
senting a source of bias.
The results obtained in this work sustain the rationale
of μFAT application to tendon disorders and they may pro-
vide evidences for the interpretation of future clinical data,
identifying the possible mechanisms involved in μFAT-
mediated effects on tendon healing. A clinical trial is now
ongoing for the evaluation of the possible clinical benefit
of μFAT injection as adjuvant therapy in the arthroscopic
rotator cuff repair, especially in terms of possible reduction
of retears.
5. Conclusions
In an inflammatory context, TCs demonstrated a catabolic
and profibrosis pattern of gene expression, while at the same
time, producing molecules with a role in tissue healing. The
coculture with μFAT not only reduced the expression of
fibrosis and catabolic markers but it also enhanced the pro-
duction of cytokines and growth factors able to counteract
the inflammatory process and to contribute to tissue regener-
ation. These observations provide a rationale for the clinical
application of μFAT in the treatment of tendon disorders.
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